Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorigerlimab Phase 1 Dose Escalation and Expansion in Advanced Solid Tumors
NCT03761017Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Dec 2018
- Primary completion
- Aug 2024
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of lorigerlimab in solid tumor (advanced stage), non-small cell lung cancer, squamous cell carcinoma (sqNSCLC), metastatic castration-resistant prostate cancer (mCRPC) and 2 more, sponsored by MacroGenics. Primary endpoint: Incidence of treatment-emergent adverse events. Started Dec 2018; status: completed.
02
Drugs
lorigerlimab
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer, squamous cell carcinoma (sqNSCLC)metastatic castration-resistant prostate cancer (mCRPC)cutaneous melanoma (CM)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03761017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761017.